VBI Vaccines Inc. (NASDAQ:VBIV) Sees Significant Growth in Short Interest

VBI Vaccines Inc. (NASDAQ:VBIV) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 709,500 shares, an increase of 145.4% from the March 31st total of 289,100 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 445,600 shares, the short-interest ratio is currently 1.6 days.

VBI Vaccines Trading Down 4.2 %

VBI Vaccines stock opened at $0.57 on Friday. VBI Vaccines has a 1-year low of $0.45 and a 1-year high of $3.47. The firm has a 50-day moving average of $0.61 and a 200-day moving average of $0.61. The firm has a market cap of $16.32 million, a P/E ratio of -0.05 and a beta of 1.93.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of VBI Vaccines in a report on Friday. They set a “sell” rating for the company.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.